EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia

S Fujieda, C Wang, M Yoshikawa, M Asako, I Suzaki, C Bachert, J K Han, A Fuller, L Baylis, L Su, E Sasaki, A R Sousa und 2 weitere

Rhinology Journal · 2024

DOI: 10.4193/rhin24.156 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Rhinology Journal, 2024. Verfasst von S Fujieda und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, University of Fukui, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Nasal Polyps. Die Arbeit wurde bisher 23-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This randomised, double-blind, placebo-controlled, parallel-group, 52-week Phase III study (MERIT; NCT04607005) assessed mepolizumab efficacy and safety in patients with chronic rhinosinusitis with nasal polyps (CRSwNP)/eosinophilic CRS (ECRS) in Japan, Russia, and China, for which data are limited. Methodology: Eligible patients (enrolled at 60 centres) had blood eosinophil count >2%, endoscopic bilateral NP score ≥5, nasal obstruction visual analogue scale (VAS) score >5, ≥2 sinonasal symptoms, and either previous sinus surgery or systemic corticosteroid use/intolerance. Patients were randomised (1:1) to receive mepolizumab 100 mg subcutaneously or placebo every 4 weeks, plus standard of care. Co-primary endpoints: change from baseline in total endoscopic NP score (ENPS) (Week 52) and nasal obstruction VAS score (Weeks 49–52). Post hoc analyses conducted in a modified intent-to-treat (mITT) population excluded patients from two study sites, related to Good Clinical Practice violations by the Site Management Organisation overseeing these sites. These were considered the primary efficacy analyses.

Results

In the mITT population, mepolizumab (n=80) versus placebo (n=83) significantly improved nasal obstruction VAS score from baseline to Week 49–52 and was associated with a trend of total ENPS improvements at Week 52. Mepolizumab/placebo on-treatment adverse events (AEs) occurred in 68/84 and 65/85 patients in the safety population (treatment-related AEs: 2/84 and 5/85, respectively), and on-treatment serious AEs in 0/84 and 4/85 patients, respectively (no fatalities reported).

Conclusions

Mepolizumab was effective and well-tolerated in patients with CRSwNP/ECRS from Japan, Russia, and China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSinusitisNasal PolypsHumansDouble-Blind MethodChinaMaleFemaleMiddle AgedAdultRussiaJapanChronic DiseaseRhinitisTreatment Outcome

Substanzen

mepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, University of Fukui, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, China.
  • Department of Otorhinolaryngology, Toho University Ohashi Medical Centre, Japan.
  • Department of Otolaryngology, Kansai Medical University, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Showa University, Japan.
  • ENT Department, University of Munster, Germany.

Zitieren

APA

Fujieda, S., Wang, C., Yoshikawa, M., Asako, M., Suzaki, I., Bachert, C., Han, J. K., Fuller, A., Baylis, L., Su, L., Sasaki, E., Sousa, A. R., Chan, R., & Zhang, L. (2024). Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. Rhinology Journal. https://doi.org/10.4193/rhin24.156

Vancouver

Fujieda S, Wang C, Yoshikawa M, Asako M, Suzaki I, Bachert C, et al. Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. Rhinology Journal. 2024. doi:10.4193/rhin24.156

BibTeX
@article{Fujieda2024,
  author = {Fujieda, S and Wang, C and Yoshikawa, M and Asako, M and Suzaki, I and Bachert, C and Han, J K and Fuller, A and Baylis, L and Su, L and Sasaki, E and Sousa, A R and Chan, R and Zhang, L},
  title = {Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia},
  journal = {Rhinology Journal},
  year = {2024},
  doi = {10.4193/rhin24.156}
}
Kostenlos starten →